Covaxin is 77.8 against Covid-19: According to lancet study

Analysis information on the protection and efficacy of India Biotech’s vaccine against Covid-19, Covaxin, following its phase 3 clinical trials, has been peer-reviewed and printed within the medical journal, The Lancet.

This came four months after the India-based company showed in a published preprinted study that its coronavirus disease vaccine was 77.8% effective against symptomatic cases and 93.4% against cases of severe symptomatic. According to the study, efficacy data for the entire virion-activated vaccine further demonstrates 63.6% protection against asymptomatic disease and 65.2% protection against the B.617.2 Delta variant. “The Lancet peer review confirms the efficacy analysis showing that Covaxin is effective against Covid19. Covaxin is the only Covid19 vaccine to have demonstrated efficacy data from phase 3 clinical trials against the Delta variant at age 65.2%, "Bharat Biotech said in a statement after The Lancet released the study on Friday.

The phase three trial efficacy and safety study concerned 25,800 volunteers across 25 sites in India. in keeping with the corporate, Covaxin was well tolerated and also the knowledge Safety observation Board didn’t report any safety considerations concerning the vaccinum. “The safety profile of Covaxin is currently well established supported inactivated vaccines technology, and in massive part because of the intensive 25-year safety log of Asian country Biotech’s vero cell producing platform,” the company same in its statement. On November 3, the vaccine was granted emergency-use listing by the globe Health Organization (WHO), giving various countries to expedite their own restrictive nods to import Covaxin vials.